Logo
Published Expertise
1989
  1. Wieckhorst, G,. Latza, R., Szypula, C., Theiß, U., Ulmer, J., Lücker, P.W. A change in Biotransformtaion Phase II from Glucuronide Conjugation to Suiphatide Conjugationas Toxicological Sig.  Lecture, IV. World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, July 23-28, 1989
  2. Ulmer, J., Szypula, C., Theiß U., Wieckhorst, G. Lücker, P.W.Simultaneous Measurement of Peripheral Blood Flow Comparing Impedance Plethysmography and Laser Doppler Flowmetry. Poster, IV. World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, July 23-28, 1989.
  3. Hasibeder, H., Staab, H.J., Seibel, K., Heibel, B., März, W., Theiß, U., Lücker, P.W. The Clinical Pharmacology of K 1.148 in Healthy Subjects. Poster, X. International Symposium On Drugs Affecting Lipid Metabolism, Houston, Texas/USA, November 8-11, 1989
  4. Bickel U, Thomsen T, Fischer JP, Kewitz H. Galanthamine: pharmacokinetics and inhibition of cholinesterases in humans. In: Kewitz H, Thomsen T, Bickel U, (eds): Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Klinische Pharmakologie. München; San Francisco: W. Zuckschwerdt Verlag 1989; 280-283.
  5. Cuprunov M, Fink P, Drakoulis N, Nitz M, Thomsen T, Roots I. Evaluation of a new dihydropyridine calcium channel blocker, diperdipine, in four phase-I studies. Florence - Italy:  4th International Symposium on Calcium Antagonists, 25.-27.05.1989; 1989.
  6. Cuprunov M, Thomsen T, Fink P, Roots I. Phase-I evaluation of diperdipine, a new dihydroperidine calcium channel blocker. Eur J Clin Pharmacol 1989; 36: Suppl.: A 336.
  7. Halabi A, Linde M, Zeidler H, König J, Kirch W. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives. Cardiovascular Drugs and Therapy 1989; 3: 441-443.
  8. Halabi A, Zurborn KH, Kaiser P, Proppe D, Kirch W. Haemostaseological parameters and circadian blood pressure values in hypertensives on chronic celiprolol administration. 23rd Annual Scientific Meeting, Athens, 19-22 April 1989. Europ J Clin Invest 19: A44, 242; 1989.
  9. Halabi I, Gebühr U, Nokhodian A, Linde M, Halabi A, Kirch W. Hemodynamic measurements on different doses of brefanolol, an alpha- and beta- blocking agent. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A136, PP02.07; 1989.
  10. Kirch W, Halabi A, Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by non-invasive hemodynamic measurements. Gastroenterology 1989; 96: 1388-1393.
  11. Kirch W, Nokhodian A, Halabi A, Linde M, Dylewicz P. Diltiazem and nitrendipine. Comparison of their haemodynamic effects. 18th Annual Meeting of the American College of Clinical Pharmacology, 11-14 October 1989. J Clin Pharmacol 290:839; 1989.
  12. Kirch W, Nokhodian A, Schacht A, Halabi A. Effects of anipamil on renal function in hypertensives. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A86, OP28.03; 1989.
  13. Nokhodian A, Halabi A, Kirch W. Barucainid bei Patienten mit normaler und eingeschränkter Nierenfunktion 1989. CorVas 4: 105-108.
  14. Nokhodian A, Linde M, Halabi A, Kirch W. Influence of barucainide on renal function and hemodynamic parameters in patients with kidney disease. IV World Conference on Clinical Pharmacology & Therapeutics, Mannheim-Heidelberg, 23-28 July 1989. Euro J Clin Pharmacol 36: (Suppl.): A203, PP06.59; 1989.
  15. Pleul O, Rost L, Thomsen T, Kewitz H. Increase of prostaglandins in rat brain by tetrahydroaminoacridine or galanthamine. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 288-291.
  16. Pleul O, Rost L, Bickel U, Thomsen T. Are prostaglandins an indicator of acetylcholine release in the brain in vivo? IVth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, July 23-28, 1989. Eur J Clin Pharmacol; 36: Suppl:A78.
  17. Pleul O, Rost L, Thomsen T, Kewitz H. On the correlation of acetylcholine (ACh) and prostaglandin E2 (PGE2) levels in the rat brain after tetrahydroacridine (THA). Naunyn Schmiedebergs Archives of Pharmacology Suppl. to Vol. 339, R 85. 1989.
  18. Pleul O, Rost L, Thomsen T, Weber W, Kewitz H. Correlation between blood and tissue levels of tetrahydroaminoacridine, cholinesterase inhibition and acetylcholine increase in the brain. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag; 1989. 292-297.
  19. Thomsen T, Kewitz H. Galanthamine treatment in senile dementia of Alzheimer's type. A case report. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 238-241.
  20. Thomsen T, Kewitz H. Comparison of acetyl- (EC 3.1.1.7, AChE) and butyryl- (EC 3.1.1.8, BuChE) cholinesterase inhibition as due to reversible enzyme inhibitors. 8th International Congress of Clinical Enzymology, May 30 – June 1, 1989, Toronto, Canada. Clin Biochem; 22:411.
  21. Thomsen T, Bickel U, Kewitz H. Pharmacokinetic and pharmacodynamic data for galanthamine in the treatment of Alzheimer's disease. Berlin (West): Jahrestagung der Deutschen Gesellschaft für Klinische Chemie, October 8-11, 1989, Berlin (West). (Abstract): J Clin Chem Clin Biochem 27:769 (1989).
  22. Thomsen T, Kewitz H, Pleul O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme 1989; 42:219-224.
  23. Thomsen T, Zendeh B, Bickel U, Kewitz H. Inhibition of acetyl- and butyrylcholinesterase as induced by various reversible enzyme inhibitors in vitro. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt Verlag 1989; 284-292877.
1988
  1. Cuprunov M, Thomsen T, Fink P, Scheiffele R, Heger-Mahn D, Weber W, Rost L, Roots I. Tolerance of a new dihydroperidine Ca++- channel blocker, diperdipine, in healthy volunteers. Naunyn Schmiedebergs Arch Pharmakol 1988; Suppl. to Vol. 338:R79.
  2. Daldrup T, Thomsen T, Reudenbach G. Cannabiskonsum – Nachweisbarkeitsdauer, zeitlicher Verlauf, forensische Bedeutung. In: Arnold W, Poser WE, Möller MR (eds). Suchtkrankheiten. Diagnose, Therapie und analytischer Nachweis. Springer, Berlin 1988; pp 39-51.
  3. Davies BE, Eckl KM, Greb WH, Mellows G, Thomsen T. The pharmacokinetics of BRL 34915, a new antihypertensive agent, in healthy male subjects. Br J Clin Pharmacol 1988; 25:136-137.
  4. Greb WH, Buscher G, Köster FE, Nix N, Sourgens H, Thomsen T. A study to test the effect of diproteverine on the thyroid in normal volunteers. The British Toxicology Society. 1988.
  5. Halabi A. Der Einfluss von Famotidin auf die Pharmakokinetik von Nifedipin und auf nicht-invasive hämodynamische Parameter. Dissertation med., Kiel 1988.
  6. Halabi A, Ohnhaus EE, Kirch W. Influence of famotidine on non-invasive hemodynamic parameters and nifedipine plasma levels. 22nd Ann. Sci. Meet. Europ. Soc. Clin. Invest. Graz, 21-23 April 1988. Europ J Clin Invest 18: A23, 99; 1988.
  7. Kirch W, Halabi A, Ohnhaus EE. Negative-inotrope Wirkung von Famotidin. Schweizerische Medizinische Wochenschrift 1988; 118: 1912-1916.
  8. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. Meeting of the British Society of Pharmacology, London 6.-8.1. 1988. Abstract Volume, Abstr. C79; 1988.
  9. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. 89th Meeting of the American Society of Clinical Pharmacology and Therapeutics, San Diego 9-11. March 1988. Clin Pharmacol Ther 43:163 IIA-3; 1988.
  10. Thomsen T, Kewitz H, Pleul O. Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring the in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 1988; 26:469-475.
  11. Thomsen T, Kewitz H, Zendeh B. Effects of various reversible inhibitors on the butyryl (EC 3.1.1.8) and acetyl (EC 3.1.1.7) cholinesterase in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmakol 1988; Suppl. to Vol. 337:R94.
  12. Tolksdorf W, Reinhard F, Hartung M, Baumann S. Vergleichende Untersuchung zu Wirkungen und Nebenwirkungen von Midazolam-Ketamin-Kombinationsnarkosen und einer Thiopental-induzierten Enfluran-Lachgasnarkose für kleinere gynäkolologische Eingriffe. Anaesthesiologie und Intensivmedizin Band 198. Neue Aspekte zu Ketamin in der Anästhesie, Intensiv- und Notfallmedizin. Abstract. Springer-Verlag 1988.
  13. Wetzelsberger N, Lucker PW, Erking W. Internally standardized method for the determination of nalbuphine in human plasma by means of high performance liquid chromatography with electrochemical coulometric detection. Arzneimittelforschung 1988; 38(12):1768-1771..
1987
  1. Darius H, Thomsen T, Schrör K. Cardiovascular actions in vitro and cardioprotective effects in vivo of nileprost, a mixed type PGI2/PGE2 agonist. J Cardiovasc Pharmacol 1987; 10:144-152.
  2. Kirch W, Halabi A, Ohnhaus EE. Negative inotropic effects of famotidine. Lancet 1987; II, 684.
  3. Koch S, Schultz A, Koch N. The production of recombinant HLA-DR beta and invariant chain polypeptides by cDNA expression in E. coli. J Immunol Methods 1987; 103:211-20.
  4. Thomsen T. Kardioprotektive Wirkungen natürlicher und synthetischer Prostaglandine in vivo in Abhängigkeit von der Ischämiedauer. Medizinische Fakultät der Universität zu Köln; 1987.
1986
  1. Tolksdorf W, Baumann S, Heine C, Hettenbach A. Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients. Anasth Intensivther Notfallmed. Abstract 1986 Dec; 21(6):301-6. German.
  2. Wetzelsberger N, Lucker PW, Erking W. High-pressure liquid chromatographic method for the determination of hydromorphone in human plasma with electrochemical detection. Arzneimittelforschung 1986; 36(11):1707-1710.
1981 - 1985
  1. Schrör K, Thiemermann C, Thomsen T, Ohlendorf R, Darius H, Gallenkämper W, Smith III EF. Beneficial effects of iloprost (ZK 36374) in experimental myocardial infarction. Mechanisms and their possible significance. In: Schering AG, editor. Iloprost (ZK 36374) a Novel Prostacyclin Analogue in Cardiovascular disease. Paoletti R (ed). Schering AG; 1985.
  2. SmithIII EF, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K. Early and late administration of a PGI2 analogue, ZK 36374 (Iloprost): Effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 1984; 18:163-173.
  3. Schrör K, Thomsen T, Ohlendorf R, Darius H, Ahland B, Kahlen T. Beneficial effects of a novel prostacyclin analogue, Nileprost or ZK 34798 in acute myocardial ischemia. 5th International Conference on Prostaglandins 1982, Florence: 276.
  4. Schrör K, Thomsen T. Cardioprotective action of a new carbacyclin derivative (ZK 36374) after 2 and 4 h of myocardial infarction. Naunyn Schmiedebergs Arch Pharmakol 1982; Suppl. to Vol. 319:R31.
  5. Schrör K, Thomsen T. Kardioprotektive Wirkungen von Prostacyclin (PGI2) nach 2 und 4 Stunden bestehender Myokardischämie im Tierversuch. Z Kardiol 1981; 70:631.
FooterEnd